SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?


To: elmatador who wrote (131746)3/8/2017 3:31:37 AM
From: Snowshoe  Read Replies (4) | Respond to of 217591
 
Elmat, some of us have been around here long enough to remember that you copied your thread idea from tradermike_1999! ;)



To: elmatador who wrote (131746)3/8/2017 3:23:14 PM
From: TobagoJack  Respond to of 217591
 
elmat, you, undisputed founder of this thread, abdicated management but certainly not and never once banned, assuredly remain in good standing with the thread.

the thread philosophy may be different than you intended or perhaps even expected, but please know that the thread in aggregate is just / equitable / fair, and recognises that many have much to contribute over a long span of time on subjects none can be expert on for all subjects all the time

the thread organically maintains itself for the greater good, and i do not think of it as my thread. i am the reluctant mc designated by you.

history is important to me, i remember, and i serve to my best ability

cheers, tj



To: elmatador who wrote (131746)3/10/2017 2:24:50 AM
From: TobagoJack  Respond to of 217591
 
re <<and he is going to go around saying: I was astute. I have a thread.>>

neah. the thread is a global common, administrated by me, because its originator was not able, either due to capability or capacity.

in the mean time i read back this post from long-enough ago Message 26469359
re <<real income in process of doubling again w/i 8-10 years>> from a posting 2010 04 17

and by the looks of ...

- tradingeconomics.com , and

- tradingeconomics.com

all seem to indicate everything tracking quite well, calibrated fine, and aligned proper

and

given so, have no particular reason to change stance w/ to 2026 and 2032, and guessing the next 30 years should be quite good whatever the hiccups in the interim.



To: elmatador who wrote (131746)4/9/2017 7:42:47 AM
From: TobagoJack  Read Replies (1) | Respond to of 217591
 
On schedule, pebble bed reactor, that which is melt-down-proof / manufactured in factory (as opposed to built in site out of concrete), and is loaded w/ easy-to-handle fuel encased in graphite, is being loaded for demo-plant, by China-natural-size standard, at 210 Mega-watt.

The time of China as net energy export is getting closer ...

Isn't it wonderful!? Am guessing each pebble bed reactor, whether fitting into a refrigerator-sized box or stacked modular in 40' containers would equal to some number of plastic flowers and a bunch of t-shirts. Even better, the fuel balls would be a recurring revenue source.

world-nuclear-news.org

Fuel loading starts at Chinese demonstration HTGRThe loading of spherical fuel elements has begun at China's Shidaowan HTR-PM - a high-temperature gas-cooled reactor (HTGR) demonstration project. The unit is scheduled to begin operating later this year.


Workers inspect the spherical fuel elements prior to their loading (Image: CNI23)

The first of the graphite spheres was loaded within the reactor's core on 5 April, China Nuclear Industry 23 Construction Company Limited (CNI23) announced today.

Each of the graphite spheres is 60 millimeters in diameter and weighs about 0.192 kilograms. Every fuel element contains 7 grams of heavy metal. The enrichment of U-235 is 8.5%. The uranium kernels - about 0.5mm in diameter - are coated by three layers of pyro-carbon and one layer of silicon carbon. The coated fuel particles are dispersed in matrix graphite which is 5cm in diameter. Surrounding the fuel-containing graphite matrix is a 5mm thick graphite layer.

CNI23 said the reactor cavity will be filled with a total of 245,318 fuel elements, to a depth of over 11 meters.

In 2005, a prototyping fuel-production facility was constructed at the Institute for Nuclear and New Energy Technology with an annual capacity of 100,000 fuel elements. Construction of the HTGR fuel-production factory in Baotou, Inner Mongolia, started in 2013. Commissioning and trial production began at the plant in 2015. An irradiation test of five fuel spheres for the HTR-PM started in October 2012 in the High Flux Reactor in Petten, the Netherlands, which was completed in December 2014.

Work on two demonstration HTR-PM units at China Huaneng Group's Shidaowan site near Weihai city in China's Shandong province, began in December 2012. The plant will initially comprise twin HTR-PM reactor modules driving a single 210 MWe steam turbine.

A proposal to construct two 600 MWe HTR plants - each featuring three twin reactor and turbine units - at Ruijin city in China's Jiangxi province passed a preliminary feasibility review in early 2015. The design of the Ruijin HTRs is based on the smaller Shidaowan demonstration HTR-PM. Construction of the Ruijin reactors is expected to start next year, with grid connection in 2021.

China has been actively promoting its HTR technology overseas and has already signed agreements with other countries - including Saudi Arabia, South Africa and the UAE - to consider the construction of HTGR plants. Last August, China Nuclear Energy Engineering Group signed an agreement with Indonesia's National Atomic Energy Agency (Batan) to jointly develop an HTGR in Indonesia.

Researched and written
by World Nuclear News



To: elmatador who wrote (131746)4/10/2017 10:42:05 PM
From: TobagoJack  Read Replies (1) | Respond to of 217591
 
watch & brief on biotech

sure beats exporting bespoke plastic flowers, or cars as a btw

am guessing lot more in the pipe per natural size

culturally speaking, what do you think?

wsj.com

China Emerges as Powerhouse for Biotech DrugsGlobal drugmakers join with local Chinese startups to test and create new cancer treatments
Preetika RanaApril 10, 2017 5:30 a.m. ET

Why Big Pharma Is Turning to Biological Drugs

Drugs are classified into two major categories based on their genetic makeup: chemical and biological. The WSJ’s Preetika Rana explains what their differences are and why drug companies are increasingly looking to biologics. Photo/video: Menglin Huang/The Wall Street Journal

By
Preetika Rana

SUZHOU, China—A new cancer drug licensed by Eli Lilly LLY 0.18% & Co. was discovered by a six-year-old startup on the outskirts of Shanghai, and derived from the ovary cells of Chinese hamsters. Lilly now is planning to test it on Americans.

Rival Merck & Co. aims to test a separate cancer drug in the U.S. this year, created by another startup near the border with Hong Kong.

Those aren’t outliers. China, long the world’s supplier of cheap pharmaceutical ingredients and copycat pills, is emerging as a major producer of important new medicines: biotech drugs. China now boasts the second-largest number of clinical trials involving biologic treatments—produced using biological matter such as animal cells or bacteria—after the U.S., according to data from the National Institutes of Health.



The world’s biggest drug companies have taken notice.

Merck sent executives to scour scores of Chinese startups, and set up a dedicated innovation center in Shanghai in 2015. Johnson & Johnson opened a similar center in Shanghai in 2014 to identify scientific breakthroughs in China. In the past two years, Lilly, Merck, Tesaro Inc. and Incyte Co. have signed multimillion-dollar deals to sell China-discovered biotech drugs overseas.

The tie-ups are a boost for China’s ambition to shake off a history of scandals, such as a 2008 incident when a blood thinner called heparin—made with Chinese ingredients—killed dozens of people in the U.S. alone. China is working to overcome a reputation for poor quality to become an innovator and global producer of complex products.

Will China transform “overnight? The answer is definitely no,” said Olivier Charmeil, Sanofi SA’s head of emerging markets. But “when a direction has been set, it’s clear that things happen,” he added, noting that China is devoting resources to ramp up quality.

However, Chinese factories supplying chemical-drug ingredients around the world continue to fail U.S. regulatory inspections. Last year, the U.S. Food and Drug Administration barred ingredients from a Chinese supplier that counts Sanofi, Pfizer Inc. and Novartis AG as its customers.



Biologic drugs differ from chemical medicines and have revolutionized treatment of diseases including cancer and diabetes. They were developed by Western drugmakers in their own laboratories for decades and are highly profitable—accounting for eight out of the world’s top 10 best-selling drugs—according to consultancy Frost & Sullivan. But the drugs require more than $1 billion each to develop and can take more than a decade to bring to market, according to Pharmaceutical Research and Manufacturers of America, a trade group.

Under pressure from a string of expensive failures and a shrinking pool of patent-protected biotech drugs, global drugmakers are increasingly turning outward to find new breakthroughs.

Enter China. As part of a push to transform the homegrown drug industry, Beijing has thrown money and incentives at Chinese drug manufacturers: One program lured back Chinese scientists working overseas, billions of dollars were poured into technology parks dedicated to biotech startups, and drug-testing approvals for new biotech discoveries were speeded up.

Most Chinese startups began by making copies or tweaked versions of existing biotech drugs, but some are advancing to the riskier business of creating biologics that haven’t been tested on humans before.

Innovent Biologics Inc., the six-year-old startup near Shanghai, struck the biggest deal to date for a Chinese drug firm in 2015, when Lilly paid it $56 million to co-develop three cancer drugs, including two discovered by Innovent. Innovent stands to earn more than $1.4 billion over the next decade if the drugs meet targets.



Michael Yu, founder of Chinese startup Innovent Biologics Photo: Innovent Biologics

Inside a small Innovent lab in the industrial town of Suzhou, dozens of cylindrical glass vessels called bioreactors brim with cells derived from Chinese hamsters, rodents commonly used in global medical research. The drug being designed, part of the Lilly deal, is meant to block a gene hindering the body’s ability to fight cancer.

The process begins by genetically modifying hamster ovary cells so that they produce an antibody—or protein—needed to block the gene. The cells are then placed inside these bioreactors, multiplying into billions of new cells over two weeks. The resulting amber-colored liquid contains large quantities of the antibody, the main ingredient in Innovent’s drug.

One recent afternoon, researchers were running tests to check the antibody for purity, color and consistency. “You have to get every step right,” said Innovent’s founder, Michael Yu, inspecting results on a screen. Finally, the antibody is packed into hundreds of tiny vials and ready to be injected into patients.

Innovent has begun testing the drug on patients in China, while Lilly is preparing an application to begin its own clinical trial in the U.S. Once the drug is approved, Lilly says it plans to sell it across the globe, except in China, where it holds joint marketing rights with Innovent.

Clinical trials—which involve testing the drug on hundreds of patients over three phases—can last over a decade in the U.S., and it is only after promising results that companies seek regulatory approval.



Scientists at Akeso Biopharma, a Chinese startup, inspect a cancer molecule. Photo: Akeso Biopharma

Gaining drug approval in the U.S. makes it easier for companies to sell products in several other countries without having to conduct separate tests in each market. China requires its own tests, though trials here are typically shorter and require fewer patients than in the U.S., according to ChinaBio, a Shanghai-based consultancy.

To be sure, not everyone is looking to license Chinese discoveries. Amgen Inc. and MedImmune Inc., AstraZeneca PLC’s biotech arm, have formed joint ventures with local companies to bring their own discoveries to China. Pfizer is building a plant to sell copies of biotech drugs in China.

Nevertheless, China’s biotech boom has attracted venture capitalists, contributing to a record $5.3 billion being invested in the country’s life sciences sector last year, a nearly 10-fold increase from five years ago, according to ChinaBio.

Lilly set up a venture-capital arm for Asia in 2008 and almost all of its $500 million in investment since has gone to Chinese biotech startups.

“China wasn’t even on the radar 10 years ago,” said Judith Li, a partner at the fund. “Now it’s impossible to ignore.”

Write to Preetika Rana at preetika.rana@wsj.com



To: elmatador who wrote (131746)4/11/2017 8:05:03 PM
From: TobagoJack  Respond to of 217591
 
more exportables on way, per 2.0 natural size etc etc



scmp.com

Chinese firm halves worker costs by hiring army of robots to sort out 200,000 packages a dayA viral video showing an army of little orange robots sorting out packages in a warehouse in eastern China is the latest example of how machines are increasingly taking over menial factory work on the mainland.

The behind-the-scenes footage of the self-charging robot army in a sorting centre of Chinese delivery powerhouse Shentong (STO) Express was shared on People’s Daily’s social media accounts on Sunday.

The video showed dozens of round orange Hikvision robots – each the size of a seat cushion – swivelling across the floor of the large warehouse in Hangzhou, Zhejiang province.

A worker was seen feeding each robot with a package before the machines carried the parcels away to different areas around the sorting centre, then flipping their lids to deposit them into chutes beneath the floor.

The robots identified the destination of each package by scanning a code on the parcel, thus minimising sorting mistakes, according to the video.

The machines can sort up to 200,000 packages a day and are self-charging, meaning they can operate around the clock.

An STO Express spokesman told the South China Morning Post on Monday that the robots had helped the company save half the costs it typically required to use human workers.

They also improved efficiency by around 30 per cent and maximised sorting accuracy, he said.

“We use these robots in two of our centres in Hangzhou right now,” the spokesman said. “We want to start using these across the country, especially in our bigger centres.”

Although the machines could run around the clock, they were presently used only for about six or seven hours each time from 6pm, he said.

Manufacturers across China have been increasingly replacing human workers with machines.

The output of industrial robots in the country grew 30.4 per cent last year.

In the country’s latest five-year plan, the central government set a target aiming for annual production of these robots to reach 100,000 by 2020.

Apple’s supplier Foxconn last year replaced 60,000 factory workers with robots, according to a Chinese government official in Kunshan, eastern Jiangsu province.

The Taiwanese smartphone maker has several factories across China.



To: elmatador who wrote (131746)4/11/2017 8:07:30 PM
From: TobagoJack1 Recommendation

Recommended By
Snowshoe

  Respond to of 217591
 
pole-climbers replaced by machines costing a few hundred at most



digitaltrends.com

China has a flamethrower drone, and a surprisingly good use for it

Why it matters to you
As drone technology develops, we can only marvel — or in some cases feel a little concerned — at the myriad of uses industry is finding for such machines.

In the exciting world of remotely controlled multi-rotor flying machines — known popularly as “drones” — an increasing number of businesses are waking up to the idea that the technology could prove useful in their own line of work.

Already, movie production outfits big and small are making full use of camera-equipped drones, while other industries such as entertainment, agriculture, and real estate are also looking to incorporate the unmanned aerial vehicles into their operations.

Of course, regulatory hurdles still play a major part in the extent to which the technology can be used by commercial bodies, a matter that continues to present Amazon with huge challenges as it seeks to launch a drone-based delivery service.

In China, however, these hurdles appear to be about as high as your knee, certainly if this electric power maintenance company in Xiangyang is anything to go by.

In a usage that would have the Federal Aviation Administration breaking into a cold sweat if the proposal ever landed on its desk, the Chinese firm has attached a flamethrower to an octocopter to clear trash caught on power lines. Perhaps other solutions were deemed too, well … dangerous?

More: Watch this flamethrower take on a liquid nitrogen freeze gun

In a video demonstration (above), we can see the copter flying close to some trash caught on the power line before the attached incendiary device lets rip, reducing the debris to a puff of black smoke. The pilot in the video looks confident enough handling the flamethrower drone, though there’s one brief moment where, as the machine returns to the ground, a colleague appears to scuttle nervously out of the way.

Clearly, holding the controller of this thing would be a good time to bring up the issue of a pay raise with your boss.

Whether you think the trash-clearing flamethrower is an ingenious idea or rather foolhardy likely depends on your attitude toward risk, but for the time being at least, this particular company seems perfectly happy with its new fire-spewing toy.




To: elmatador who wrote (131746)4/21/2017 7:03:41 PM
From: TobagoJack  Respond to of 217591
 
interesting follow-up to china 2.0

as savings, production, investments, and infrastructure may still be the way to go, as opposed to consumption and dissipation

scmp.com
With or without Trump, China’s export machine is remaking itself as hi-tech gadgets dominate Canton fair

PUBLISHED : Friday, 21 April, 2017, 11:17am
UPDATED : Friday, 21 April, 2017, 11:05pm



The first phase of the latest Canton trade fair, a major event for Chinese exporters seeking to woo overseas buyers for the last six decades, felt like a hi-tech show with thousands of booths displaying smart devices and gadgets.

In contrast to earlier editions when the fair’s shelves were filled with cigarette lighters, shovels or zippers that were relatively cheap and easy to make, the popular products at phase one of the fair, which ended on Wednesday in Guangzhou, formerly called Canton, are such items as virtual reality game stations and massive touch screens.

The booth belonging to Guangzhou NINED Digital Technology, a virtual reality game equipment maker, was one of the busiest in the massive exhibition hall that housed the electronics and mechanical products session of the 121st China Import and Export Fair as potential customers and general visitors queued to try the company’s shooting game device.

Kate Qiu, a sales manager, said the products,with prices as high as US$30,000 per unit, were popular with buyers from Europe and the Middle East.



She said the company expected to triple its sales in 2017 from a year earlier on “a conservative estimate”. The company, based in Guangdong, is hiring virtual reality device engineers from around the world and investing heavily in new product development, Qiu said.

A few metres away, Shenzhen iBoard Technology was promoting an “interactive white board” priced at US$300 and an 84-inch touch screen priced at US$4,000. Sales manager Jessica Zhu was explaining to potential clients how the products could be used in “smart classrooms”.

She said the products had sold well to European and US clients and the company was “actively forming partnerships with suppliers to lock in good deals” while spending large on research and development.

Such products, which require advanced technologies to make and accordingly cost more, are regearing China’s US$2 trillion export machine.

“Shoes and T-shirts are no longer what are driving China’s export engine, rather, it’s increasingly sophisticated gadgets stretching from smartphones and drones, to hover boards and semiconductors,” said Frederic Neumann, co-head of Asian economics research at HSBC.

With US President Donald Trump alleging that China deliberately made cheap exports to steal jobs from the US, many Chinese exporters, squeezed by rising domestic costs, have been trying hard to climb the value chain, and some of those efforts are paying off.

Although Chinese overseas shipments recorded a 16 per cent plunge in 2009 following the global financial crisis, Chinese exports regained momentum in the following years. In US dollar terms, the value of China’s exports in 2016, although down 7.7 per cent from 2015, was still about 50 per cent higher than in 2008.

China is now the largest trading partner for more than 120 countries. Despite a shrinking labour force, greater competition from low-cost markets such as Bangladesh and Mexico, and constant trade disputes with its major partners, China’s share of global exports has been rising.

China’s exports surged 16 per cent in March from a year earlier, generating a trade surplus of US$24 billion.

Behind the numbers is a giant export machine’s struggle to cut its dependency on low-cost production and its reliance on the traditionally rich markets of the US, the European Union and Japan.

An increasing number of young Chinese people like Qiu, the 20-something sales manager from NINED, are planning careers in technology related businesses, rather than taking a slot on an assembly line in a massive factory, and China’s economic upgrade is providing them such options.

The mainstream Chinese export picture looks less like what Leslie Chang described in her 2008 book, Factory Girls: From Village to City in a Changing China, after a decade of gradual but steady change.

“China’s exports have been upgrading over the past decade,” said Zhao Yang, the chief China economist at Nomura Securities in Hong Kong. “There is no question that the technology level of China’s exports has been increasing.”

While the chances have been slim for China to record annual double-digit export growth in the years following its entry into the World Trade Organisation in 2001, the country could still manage “single-digit growth” for years to come, Zhao said.

Neumann from HSBC said “the image of smokestack China where armies of workers toil at long assembly lines is increasingly misleading”.

“Across the Pearl River Delta, for example, an innovation culture has taken hold with manufacturing increasingly resembling that found in many developed markets,” he said.

A Bolivian factory owner, who introduced herself as Aidee, said she was attending the fair for her third time and had found something new each time.

“I can still find many new things here every year and the quality is improving every year,” she said. “[The Canton Fair] is still an important source for us to get quality at competitive prices.”

Kaumadi Uragoda from Sri Lanka was sourcing machine tools to process rubber in her home country, and said she had placed orders worth more than US$30,000 at the fair, which was crowded with Middle Eastern, African and Southeast Asian merchants.

“Normally we buy from India because it is closer but we switched to Chinese manufacturers because the price is better and the quality is also good,” Uragoda said.

Those exporters unable to reinvent themselves will suffer, as evidenced by a booth carrying fly swatters, which had a notable lack of visitors.



Hunter Dai, the owner of keyboard manufacturer Shenzhen SQT Electronics, said surging costs for rent, raw materials and labour were making his business harder than it had been since he founded the company a decade ago.

Dai said he relied on government tax rebates for exporters to survive. “All my 6 per cent margin came from the government tax rebates for exports,” he said.

Liao Qun, chief economist at China Citic Bank International, said it was “unavoidable” that labour-intensive manufacturing would wither in China as low-cost production was gradually relocating to Southeast Asia and even Africa.

“China hopes the process will be slow, keeping some low-end manufacturing at home while churning out more products in the fields of IT, AI and the Internet, because that’s where the future is heading,” Liao said.

Additional reporting by Sidney Leng